CC BY-NC-ND 4.0 · J Neuroanaesth Crit Care 2022; 09(01): 010-015
DOI: 10.1055/s-0042-1744395
Review Article

Brain Biomarkers in Patients with COVID-19 and Neurological Manifestations: A Narrative Review

Mayank Tyagi
1   Department of Neuroanaesthesiology and Critical Care, All India Institute of Medical Sciences, New Delhi, India
,
Indu Kapoor
1   Department of Neuroanaesthesiology and Critical Care, All India Institute of Medical Sciences, New Delhi, India
,
Charu Mahajan
1   Department of Neuroanaesthesiology and Critical Care, All India Institute of Medical Sciences, New Delhi, India
,
Nidhi Gupta
2   Department of Neuroanesthesia, Indraprastha Apollo Hospital, New Delhi, India
,
Hemanshu Prabhakar
1   Department of Neuroanaesthesiology and Critical Care, All India Institute of Medical Sciences, New Delhi, India
› Author Affiliations

Abstract

Acute hyperinflammatory response (cytokine storm) and immunosuppression are responsible for critical illness in patients infected with coronavirus disease 2019 (COVID-19). It is a serious public health crisis that has affected millions of people worldwide. The main clinical manifestations are mostly by respiratory tract involvement and have been extensively researched. Increasing numbers of evidence from emerging studies point out the possibility of neurological involvement by COVID-19 highlighting the need for developing technology to diagnose, manage, and treat brain injury in such patients. Here, we aimed to discuss the rationale for the use of an emerging spectrum of blood biomarkers to guide future diagnostic strategies to mitigate brain injury-associated morbidity and mortality risks in COVID-19 patients, their use in clinical practice, and prediction of neurological outcomes.



Publication History

Article published online:
27 May 2022

© 2022. Indian Society of Neuroanaesthesiology and Critical Care. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 
  • References

  • 1 Li YC, Bai WZ, Hashikawa T. The neuroinvasive potential of SARS-CoV2 may play a role in the respiratory failure of COVID-19 patients. J Med Virol 2020; 92 (06) 552-555
  • 2 WHO Coronavirus Disease (COVID-19) Dashboard. WHO Coronavirus Disease (COVID-19) Dashboard. Accessed August 24, 2021 at: https://covid19.who.int/
  • 3 Wu Y, Xu X, Chen Z. et al. Nervous system involvement after infection with COVID-19 and other coronaviruses. Brain Behav Immun 2020; 87: 18-22
  • 4 Heneka MT, Golenbock D, Latz E, Morgan D, Brown R. Immediate and long-term consequences of COVID-19 infections for the development of neurological disease. Alzheimers Res Ther 2020; 12 (01) 69
  • 5 Ferrarese C, Silani V, Priori A. et al; Italian Society of Neurology (SIN). An Italian multicenter retrospective-prospective observational study on neurological manifestations of COVID-19 (NEUROCOVID). Neurol Sci 2020; 41 (06) 1355-1359
  • 6 Aamodt AH, Hogestol EA, Popperud TH. et al. Blood neurofilament light concentration at admittance: a potential prognostic marker in COVID-19. medRxiv. 2020: 1
  • 7 Prabhakar H, Mahajan C, Kapoor I. COVID-19 and neuroinvasion. Anesth Analg 2020; 131 (02) e91-e92
  • 8 Liotta EM, Batra A, Clark JR. et al. Frequent neurologic manifestations and encephalopathy-associated morbidity in Covid-19 patients. Ann Clin Transl Neurol 2020; 7 (11) 2221-2230
  • 9 Lu L, Xiong W, Liu D. et al. New onset acute symptomatic seizure and risk factors in coronavirus disease 2019: a retrospective multicenter study. Epilepsia 2020; 61 (06) e49-e53
  • 10 Chachkhiani D, Soliman MY, Barua D. et al. Neurological complications in a predominantly African American sample of COVID-19 predict worse outcomes during hospitalization. Clin Neurol Neurosurg 2020; 197: 106173
  • 11 Romero-Sánchez CM, Díaz-Maroto I, Fernández-Díaz E. et al. Neurologic manifestations in hospitalized patients with COVID-19: the ALBACOVID registry. Neurology 2020; 95 (08) e1060-e1070
  • 12 Sierra-Hidalgo F, Muñoz-Rivas N, Torres Rubio P. et al. Large artery ischemic stroke in severe COVID-19. J Neurol 2020; 267 (12) 3441-3443
  • 13 Frontera JA, Sabadia S, Lalchan R. et al. A prospective study of neurologic disorders in hospitalised COVID-19 patients in New York City. Neurology 2020; 96: 575-586
  • 14 Paterson RW, Brown RL, Benjamin L. et al. The emerging spectrum of COVID-19 neurology: clinical, radiological and laboratory findings. Brain 2020; 143 (10) 3104-3120
  • 15 Vanderver A, Adang L, Gavazzi F. et al. Janus kinase inhibition in the Aicardi-Goutières syndrome. N Engl J Med 2020; 383 (10) 986-989
  • 16 Carrabba G, Tariciotti L, Guez S, Calderini E, Locatelli M. Neurosurgery in an infant with COVID-19. Lancet 2020; 395 (102/34) e76
  • 17 Toscano G, Palmerini F, Ravaglia S. et al. Guillain–Barré syndrome associated with SARSCoV-2. N Engl J Med 2020; 382 (26) 2574-2576
  • 18 Edén A, Kanberg N, Gostner J. et al. CSF biomarkers in patients with COVID-19 and neurologic symptoms: a case series. Neurology 2021; 96 (02) e294-e300
  • 19 DeKosky ST, Kochanek PM, Valadka AB. et al. Blood biomarkers for detection of brain injury in COVID-19 patients. J Neurotrauma 2021; 38 (01) 1-43
  • 20 Barry DM, Stevenson W, Bober BG. et al. Expansion of neurofilament medium C terminus increases axonal diameter independent of increases in conduction velocity or myelin thickness. J Neurosci 2012; 32 (18) 6209-6219
  • 21 Li W, Moore MJ, Vasilieva N. et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature 2003; 426 (69/65) 450-454
  • 22 Hoffmann M, Kleine-Weber H, Schroeder S. et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 2020; 181 (02) 271-280
  • 23 Sigrist CJ, Bridge A, Le Mercier P. A potential role for integrins in host cell entry by SARS-CoV-2. Antiviral Res 2020; 177: 104759
  • 24 Mazza MG, De Lorenzo R, Conte C. et al; COVID-19 BioB Outpatient Clinic Study group. Anxiety and depression in COVID-19 survivors: role of inflammatory and clinical predictors. Brain Behav Immun 2020; 89: 594-600
  • 25 Wu C, Chen X, Cai Y. et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med 2020; 180 (07) 934-943
  • 26 Guan WJ, Ni ZY, Hu Y. et al; China Medical Treatment Expert Group for Covid-19. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020; 382 (18) 1708-1720
  • 27 Hamming I, Timens W, Bulthuis ML, Lely AT, Navis G, van Goor H. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J Pathol 2004; 203 (02) 631-637
  • 28 Baig AM, Khaleeq A, Ali U, Syeda H. Evidence of the COVID-19 virus targeting the CNS: tissue distribution, host–virus interaction, and proposed neurotropic mechanisms. ACS Chem Neurosci 2020; 11 (07) 995-998
  • 29 Abiodun OA, Ola MS. Role of brain renin angiotensin system in neurodegeneration: an update. Saudi J Biol Sci 2020; 27 (03) 905-912
  • 30 Desforges M, Le Coupanec A, Dubeau P. et al. Human coronaviruses and other respiratory viruses: underestimated opportunistic pathogens of the central nervous system?. Viruses 2019; 12 (01) 14
  • 31 Prabhakar H, Mahajan C, Kapoor I. COVID 19 and brain crosstalks. Clin Neurol Neurosurg 2020; 196: 105991
  • 32 Rao MV, Campbell J, Yuan A. et al. The neurofilament middle molecular mass subunit carboxyl-terminal tail domains is essential for the radial growth and cytoskeletal architecture of axons but not for regulating neurofilament transport rate. J Cell Biol 2003; 163 (05) 1021-1031
  • 33 Kanberg N, Ashton NJ, Andersson LM. et al. Neurochemical evidence of astrocytic and neuronal injury commonly found in COVID-19. Neurology 2020; 95 (12) e1754-e1759
  • 34 Zetterberg H, Blennow K. Fluid biomarkers for mild traumatic brain injury and related conditions. Nat Rev Neurol 2016; 12 (10) 563-574
  • 35 Khalil M, Teunissen CE, Otto M. et al. Neurofilaments as biomarkers in neurological disorders. Nat Rev Neurol 2018; 14 (10) 577-589
  • 36 Gaetani L, Blennow K, Calabresi P, Di Filippo M, Parnetti L, Zetterberg H. Neurofilament light chain as a biomarker in neurological disorders. J Neurol Neurosurg Psychiatry 2019; 90 (08) 870-881
  • 37 Thelin EP, Zeiler FA, Ercole A. et al. Serial sampling of serum protein biomarkers for monitoring human traumatic brain injury dynamics: a systematic review. Front Neurol 2017; 8: 300
  • 38 Ameres M, Brandstetter S, Toncheva AA. et al. Association of neuronal injury blood marker neurofilament light chain with mild-to-moderate COVID-19. J Neurol 2020; 267 (12) 3476-3478
  • 39 Hansen PB, Kjeldsen L, Dalhoff K, Olesen B. Cerebrospinal fluid beta-2-microglobulin in adult patients with acute leukemia or lymphoma: a useful marker in early diagnosis and monitoring of CNS-involvement. Acta Neurol Scand 1992; 85 (03) 224-227
  • 40 Svatoňová J, Bořecká K, Adam P, Lánská V. Beta2-microglobulin as a diagnostic marker in cerebrospinal fluid: a follow-up study. Dis Markers 2014; 2014: 495402
  • 41 Pilotto A, Odolini S, Masciocchi S. et al. Steroid-responsive encephalitis in Covid- 19 disease. Ann Neurol 2020; 88 (02) 423-427
  • 42 Hegen H, Deisenhammer F. Cerebrospinal fluid biomarkers in bacterial meningitis/biomarker im liquor cerebrospinalis bei bakterieller meningitis. Lab Med 2009; 33: 321-331
  • 43 Eng LF. Glial fibrillary acidic protein (GFAP): the major protein of glial intermediate filaments in differentiated astrocytes. J Neuroimmunol 1985; 8 (04/06) 203-214
  • 44 Lee JY, Lee CY, Kim HR, Lee CH, Kim HW, Kim JH. A role of serum-based neuronal and glial markers as potential predictors for distinguishing severity and related outcomes in traumatic brain injury. J Korean Neurosurg Soc 2015; 58 (02) 93-100
  • 45 Welch RD, Ayaz SI, Lewis LM. et al. Ability of serum glial fibrillary acidic protein, ubiquitin C-terminal hydrolase-L1, and S100B to differentiate normal and abnormal head computed tomography findings in patients with suspected mild or moderate traumatic brain injury. J Neurotrauma 2016; 33 (02) 203-214
  • 46 Cooper J, Stukas S, Hoiland RL. et al. Quantification of neurological blood-based biomarkers in critically ill patients with coronavirus disease 2019. Crit Care Explor 2020; 2 (10) e0238
  • 47 Mao L, Jin H, Wang M. et al. Neurologic manifestations of hospitalised patients with coronavirus disease 2019 in Wuhan, China. JAMA Neurol 2020; 77 (06) 683-690
  • 48 Avula A, Nalleballe K, Narula N. et al. COVID-19 presenting as stroke. Brain Behav Immun 2020; 87: 115-119
  • 49 Glushakova OY, Glushakov AV, Miller ER, Valadka AB, Hayes RL. Biomarkers for acute diagnosis and management of stroke in neurointensive care units. Brain Circ 2016; 2 (01) 28-47
  • 50 Mondello S, Palmio J, Streeter J, Hayes RL, Peltola J, Jeromin A. Ubiquitin carboxy-terminal hydrolase L1 (UCH-L1) is increased in cerebrospinal fluid and plasma of patients after epileptic seizure. BMC Neurol 2012; 12: 85
  • 51 Farhadian S, Glick LR, Vogels CBF. et al. Acute encephalopathy with elevated CSF inflammatory markers as the initial presentation of COVID-19. BMC Neurol 2020; 20 (01) 248
  • 52 Reichard RR, Kashani KB, Boire NA, Constantopoulos E, Guo Y, Lucchinetti CF. Neuropathology of COVID-19: a spectrum of vascular and acute disseminated encephalomyelitis (ADEM)-like pathology. Acta Neuropathol 2020; 140 (01) 1-6
  • 53 Rothermundt M, Peters M, Prehn JH, Arolt V. S100B in brain damage and neurodegeneration. Microsc Res Tech 2003; 60 (06) 614-632
  • 54 Yardan T, Erenler AK, Baydin A, Aydin K, Cokluk C. Usefulness of S100B protein in neurological disorders. J Pak Med Assoc 2011; 61 (03) 276-281
  • 55 Ishibashi H, Funakoshi Y. Serum S-100B protein levels in left- and right-hemisphere strokes. J Clin Neurosci 2008; 15 (05) 520-525
  • 56 Gonçalves CA, Leite MC, Nardin P. Biological and methodological features of the measurement of S100B, a putative marker of brain injury. Clin Biochem 2008; 41 (10/11) 755-763
  • 57 Korfias S, Stranjalis G, Boviatsis E. et al. Serum S-100B protein monitoring in patients with severe traumatic brain injury. Intensive Care Med 2007; 33 (02) 255-260
  • 58 Moritz S, Warnat J, Bele S, Graf BM, Woertgen C. The prognostic value of NSE and S100B from serum and cerebrospinal fluid in patients with spontaneous subarachnoid hemorrhage. J Neurosurg Anesthesiol 2010; 22 (01) 21-31
  • 59 Sanchez-Peña P, Pereira AR, Sourour NA. et al. S100B as an additional prognostic marker in subarachnoid aneurysmal hemorrhage. Crit Care Med 2008; 36 (08) 2267-2273
  • 60 Aceti A, Margarucci LM, Scaramucci E. et al. Serum S100B protein as a marker of severity in Covid-19 patients. Sci Rep 2020; 10 (01) 18665
  • 61 Nakamura K, Greenwood A, Binder L. et al. Proline isomer-specific antibodies reveal the early pathogenic tau conformation in Alzheimer's disease. Cell 2012; 149 (01) 232-244
  • 62 Castellani RJ, Perry G. Tau biology, tauopathy, traumatic brain injury, and diagnostic challenges. J Alzheimers Dis 2019; 67 (02) 447-467
  • 63 Espíndola OM, Brandão CO, Gomes YCP. et al. Cerebrospinal fluid findings in neurological diseases associated with COVID-19 and insights into mechanisms of disease development. Int J Infect Dis 2021; 102: 155-162
  • 64 Ramani A, Müller L, Ostermann PN. et al. SARS-CoV-2 targets neurons of 3D human brain organoids. EMBO J 2020; 39 (20) e106230
  • 65 Kennedy R, Silver R. Neuroimmune signaling: cytokines and the CNS. In: Pfaff DW, Volkow ND. eds. Neuroscience in the 21st Century: From Basic to Clinical. 2nd ed. New York, NY: Springer; 2016: 601-641
  • 66 Bhaskar S, Sinha A, Banach M. et al. Cytokine storm in COVID-19—immunopathological mechanisms, clinical considerations, and therapeutic approaches: the REPROGRAM consortium position paper. Front Immunol 2020; 11: 1648
  • 67 Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med 2020; 46 (05) 846-848
  • 68 Bodro M, Compta Y, Llansó L. et al; “Hospital Clínic Infecto-COVID-19” and “Hospital Clínic Neuro-COVID-19” groups. Increased CSF levels of IL-1β, IL-6, and ACE in SARS-CoV-2-associated encephalitis. Neurol Neuroimmunol Neuroinflamm 2020; 7 (05) e821